Treatment of Proliferative Diabetic Retinopathy with Panretinal Photo Coagulation and Anti VEGF Injection, Depending on the Case
Abstract
Proliferative diabetic retinopathy (PDR) is the most common cause of severe visual loss in people with diabetes. Although panretinal photocoagulation (PRP) remains one of the best treatment, it has many side effects. So other new treatment modalities have emerged. These can be used to increase the extent of treatment, expedite the effect of laser treatment and provide alternate measures when laser delivery is difficult or impossible, especially in patients with vitreous haemorrhage, or when the patient is at young age. Currently, most of the research in this field is focussed on inhibitors of vascular endothelial growth factor (VEGF). Although limited by their short-lived effects, anti-VEGF agents are widely available, especially for the treatment of aggressive PDR. We present 2 cases which had regression of neovascularization within four weeks of the initial treatments, and maintained their visual acuity with no evidence of recurrent neovascularization through 12 months after initiating treatment. Intravitreous injections of anti-VEGF therapy may be an alternative treatment option for patients with PDR. We followed a system of 3 injection q4wk followed by injection q8wk, depending on gravity of macular edema and it’s regression from anti-VEGF intravitreal injections.
Keywords: PRP, PDR, VEGF, DME, etc.
References
Retina in systemic disease : a color manual of ophthalmoscopy / Homayoun Tabandeh, Morton F. Goldberg 2009.
Treatment of proliferative diabetic retinopathy with anti-VEGF agents | Request PDF. Available from: https://www.researchgate.net/publication/49811184_Treatment_of_proliferative_diabetic_retinopathy_with_anti-VEGF_agents [accessed Mar 19 2018].
Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetesin the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: 2011.
Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 Suppl):823-33.
Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Archives of ophthalmology. 2004;122(4): 552-63.
Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005; 353(8): 839-41.
Early Treatment Diabetic Retinopathy Study Research Group. Early Photocoagulation for Diabetic Retinopathy. ETDRS report number 9. Ophthalmology. 1991; 98(5): 766-85.
Jardeleza MSR, Miller JW. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Seminars in ophthalmology. 2009; 24(2): 87-92.
Downloads
Published
How to Cite
Issue
Section
License
Declaration/Copyright transfer:
1. In consideration of the undertaking set out in paragraph 2, and upon acceptance by ANGLISTICUM for publication of the manuscript in the Journal, I/We hereby assign and transfer publication rights to ANGLISTICUM, whereas I/We retain the copyright for the manuscript. This assignment provides ANGLISTICUM the sole right and responsibility to publish the manuscript in its printed and online version, and/or in other media formats.
2. In consideration of this assignment, ANGLISTICUM hereby undertakes to prepare and publish the manuscript in the Journal, subject only to its right to refuse publication if there is a breach of the Author’s warranty in paragraph 4 or if there are other reasonable grounds.
3. Editors and the editorial board of ANGLISTICUM are empowered to make such editorial changes as may be necessary to make the Manuscript suitable for publication.
4. I/We hereby acknowledge that: (a) The manuscript submitted is an original work and that I/We participated in the work substantively and thus I/We hereby are prepared to take public responsibility for the work; (b) I/We hereby have seen and approved the manuscript as submitted and that the manuscript has not either been published, submitted or considered for publication elsewhere; (c) The text, illustration, and any other materials included in the manuscript do not infringe upon any existing copyright or other rights of anyone.
5. I/We hereby indemnify ANGLISTICUM and the respective Editors of the Journal as mentioned in paragraph 3, and hold them harmless from any loss, expense or damage occasioned by a claim or suit by a third party for copyright infringement, or any suit arising out of any breach of the foregoing warranties as a result of publication of the manuscript.
